文献速递糖尿病肥胖与代谢综合征

2型糖尿病缓解:问题总是更多,但已有足够答案可付诸行动

Remission of type 2 diabetes: always more questions, but enough answers for action.
PubMed 文献 · Diabetologia · 2024-01-08

2型糖尿病缓解概念正快速演变。大幅有意减重可使近九成患者在不使用降糖药的情况下将HbA1c降至诊断标准以下并改善代谢综合征各项特征。现代减重药物有效但可及性有限,因此需探索饮食干预;有效体重管理应在诊断后尽早提供给所有2型糖尿病患者。

要点

  • 大幅有意减重可使近九成2型糖尿病患者HbA1c降至48 mmol/mol以下且无需降糖药。
  • 缓解最可能见于病程短、HbA1c较低、降糖药需求少的2型糖尿病患者。
  • 在现有证据下,所有2型糖尿病患者应在诊断后尽早获得有效体重管理。

核心结论

  • 大幅减重可使近九成2型糖尿病患者HbA1c降至48 mmol/mol(6.5%)以下且无需降糖药,并改善代谢综合征各项特征。
  • 在现有证据下,所有2型糖尿病患者应在诊断后尽早(或更早至糖尿病前期阶段)获得有效体重管理。

研究设计与样本

  • 本文为综述,围绕2型糖尿病缓解的概念、证据与研究方向进行论述。

主要发现

  • 大幅有意减重可使近九成2型糖尿病患者HbA1c降至48 mmol/mol(6.5%)以下且无需降糖药。
  • 持续性减重>10-15 kg可改善HbA1c,若β细胞容量得以保留或恢复则可能实现缓解,这与2型糖尿病中肝脏和胰腺异位脂肪减少相关。
  • 缓解最可能见于病程短、HbA1c较低、降糖药需求少的2型糖尿病患者;体重反弹和β细胞储备差者易复发。
  • 减重>10 kg且缓解持续1-2年可能延迟血管并发症,但需更多证据。

关键数值与推荐

  • 2型糖尿病诊断标准为HbA1c 48 mmol/mol(6.5%)。
  • 常规降糖治疗目标为HbA1c 53 mmol/mol(7%)。
  • 欧洲、澳大拉西亚、加拿大及世界大部分地区糖尿病前期定义为HbA1c≥42且<48 mmol/mol(≥6.0且<6.5%),美国定义为HbA1c≥39且<48 mmol/mol(≥5.7且<6.5%)。

临床怎么用

  • 现代胰高血糖素样肽-1受体激动剂及相关药物对减重和血糖改善高效且总体安全,但许多人不想长期用药,且费用使世界许多地区无法获得。
  • 在现有证据下,所有2型糖尿病患者应在诊断后尽早(或更早至糖尿病前期阶段)获得有效体重管理。
  • 提高2型糖尿病患者及其医疗提供者对缓解可能性的认识将有助于更早干预。
  • 作者认为:持续性减重>10-15 kg可改善HbA1c,若β细胞容量得以保留或恢复则可能实现缓解。

局限性

  • 减重>10 kg且缓解持续1-2年可能延迟血管并发症,但需更多证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The concept of type 2 diabetes remission is evolving rapidly, and gaining wide public and professional interest, following demonstration that with substantial intentional weight loss almost nine in ten people with type 2 diabetes can reduce their HbA1c level below the diagnostic criterion (48 mmol/mol [6.5%]) without glucose-lowering medications, and improve all features of the metabolic syndrome. Pursuing nomoglycaemia with older drugs was dangerous because of the risk of side effects and hypoglycaemia, so the conventional treatment target was an HbA1c concentration of 53 mmol/mol (7%), meaning that diabetes was still present and allowing disease progression. Newer agents may achieve a normal HbA1c safely and, by analogy with treatments that send cancers or inflammatory diseases into remission, this might also be considered remission. However, although modern glucagon-like peptide-1 receptor agonists and related medications are highly effective for weight loss and glycaemic improvement, and generally safe, many people do not want to take drugs indefinitely, and their cost means that they are not available across much of the world. Therefore, there are strong reasons to explore and research dietary approaches for the treatment of type 2 diabetes. All interventions that achieve sustained weight loss of >10-15 kg improve HbA1c, potentially resulting in remission if sufficient beta cell capacity can be preserved or restored, which occurs with loss of the ectopic fat in liver and pancreas that is found with type 2 diabetes. Remission is most likely with type 2 diabetes of short duration, lower HbA1c and a low requirement for glucose-lowering medications. Relapse is likely with weight regain and among those with a poor beta cell reserve. On current evidence, effective weight management should be provided to all people with type 2 diabetes as soon as possible after diagnosis (or even earlier, at the stage of prediabetes, defined in Europe, Australasia, Canada [and most of the world] as ≥42 and <48 mmol/mol [≥6.0 and <6.5%], and in the USA as HbA1c ≥39 and <48 mmol/mol [≥5.7 and <6.5%]). Raising awareness among people with type 2 diabetes and their healthcare providers that remission is possible will enable earlier intervention. Weight loss of >10 kg and remission lasting 1-2 years may also delay vascular complications, although more evidence is needed. The greatest challenge for research is to improve long-term weight loss maintenance, defining cost-effective approaches tailored to the preferences and needs of people living with type 2 diabetes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Rothberg A, Lean M, Laferrère B, et al. Remission of type 2 diabetes: always more questions, but enough answers for action. Diabetologia. 2024. PMID: 38189935. doi:10.1007/s00125-023-06069-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。